002821 Asymchem Laboratories
- 85.01
- +0.74+0.88%
Asymchem Laboratories News
May 8 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$32.0953 million
According to documents disclosed by the Hong Kong Stock Exchange on May 9, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 8, involving an amount of HK$32.0953 million. The repurchase price per share ranged from HK$107.7 to HK$106. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 300,000 shares, accounting for 0.016% of the number of shares issued when the ordinary resolution was passed. ② $Swire Group A
Gloria Ying (06821) spent about 49.9972 million yuan to buy back 594,000 shares on May 8
Gloria Eng (06821) announced that the company spent approximately RMB 4999.72 on May 8, 2024...
Gloria Ying (06821.HK) spent 49.97 million yuan to buy back 594,000 A shares on May 8
Glonghui, May 8 | Gloria Ying (06821.HK) announced that it spent 49.97 million yuan to buy back 594,000 A shares on May 8.
May 7 Repurchase Collection | Kuaishou-W, Hang Seng Bank and others bought back one after another, of which Kuaishou-W cost HK$49.499 million
According to documents disclosed by the Hong Kong Stock Exchange on May 8, $Kuaishou-W (01024.HK) $, $Hang Seng Bank (00011.HK) $, etc. repurchased shares. ① $Kuaishou-W (01024.HK) $ repurchased 844,000 shares of the same share with different rights on May 7, involving an amount of HK$49.499 million. The repurchase price for each share ranged from HK$59.95 to HK$58.5. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 58.722,300 shares, accounting for 1.355% of the number of shares issued when the ordinary resolution was passed. ②
Gloria Ying (06821.HK) spent 21.5957 million yuan to buy back 252,900 A shares on May 7
Glonghui, May 7 | Gloria Ying (06821.HK) announced that on May 7, 2024, it spent 21.5957 million yuan to buy back 252,900 A shares.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Gloria Ying (06821) participated in the investment fund to complete business registration
Zhitong Finance App News, Gloria Ying (06821) issued an announcement. The company held the 50th meeting of the 4th board of directors on April 29, 2024 to review and pass the “Proposal on Wholly-owned Subsidiaries to Participate in Investment Funds and Related Transactions”, agreeing to invest 30 million yuan as a wholly-owned subsidiary Gloria Life Science Technology (Tianjin) as a limited partner with Tianjin Xinyin Hengze Management Consulting Partnership (Limited Partnership), Haizunchuang (Tianjin) Enterprise Management Consulting Partnership (Limited Partnership), Tianjin Haihe Industrial Fund Partnership Limited (Limited Partnership) Partnership), Tianjin Eco-City State-owned
Gloria Ying (002821.SZ): 2.02% of shares have been repurchased cumulatively
Glonghui, May 6, 丨 Gloria Ying (002821.SZ) announced that as of April 30, 2024, the total number of shares repurchased by the company through centralized bidding through a special securities account was 6,898,369 shares, accounting for 2.0175% of the company's total A share capital. The highest transaction price was 10.2.00 yuan/share, and the minimum transaction price was 75.53 yuan/share. The total amount paid was 578 million yuan (excluding transaction fees).
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
Gloria Ying (002821): Improve quality and increase, and continue to advance various businesses
The company released its 2024 quarterly report: 2024Q1 achieved operating income of 1,400 million yuan (yoy -37.76%) and net profit to mother of 282 million yuan (yoy -55.27%), in fact
Gloria Ying (06821) plans to invest 300 million yuan to establish a biomedical innovation and synthetic biology industry investment fund with Haihe Fund, Eco-City State-owned Assets, etc.
Gloria Ying (06821) announced that in order to seize the booming development opportunities in the domestic and foreign innovative drug markets, by investing in specialized students...
A subsidiary of Gloria Incorporated (06821.HK) and CNBC Hengze jointly set up a fund
Gelonghui, April 30, 丨 Gloria Ying (06821.HK) announced that on April 29, 2024, Gloria Life Science Technology (a wholly-owned subsidiary of the company, as limited partner) signed a partnership agreement with CITIC Hengze (as general partner), Haizunchuang Enterprise Management (as general partner), Haihe Industrial Fund (as limited partner) and Tianjin Eco-City (as limited partner) to jointly establish a fund to invest in innovative biopharmaceuticals, synthetic biology and other industries in the future. According to the partnership agreement, the total amount of capital pledged by the fund is RMB 754 million, of which (i) CNBC Hengze will
Gloria Ying (002821): Excluding large orders affecting the rapid growth of the main business and waiting for the industry to gradually recover
Incident: The company released its 2024 quarterly report. In the first quarter of 2024, the company achieved operating income of 1,400 million yuan, a year-on-year decrease of 37.76%; net profit to mother was 282 million yuan, a year-on-year decrease of 55.27%; deducted from Africa
Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models
It's been a good week for Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) shareholders, because the company has just released its latest first-quarter results, and the shares gained 5.7% to CN
Gloria Ying (002821): Small molecule business continues to grow and accelerate overseas layout
Core idea: Promote the development of small-molecule CDMO and promote the rebalance of the company's overall profitability. According to the company's quarterly report, the company achieved total revenue of 1,400 billion yuan, a year-on-year decrease of 37.76%, excluding large orders for the same period last year
Gloria Ying (002821): Regular business is growing steadily, and emerging businesses continue to advance
Guide to this report: After excluding large orders, regular business grew steadily, and emerging businesses such as peptides continued to advance, optimistic about long-term growth space, and maintained an increase in holdings rating. Key investment points: Maintain an increase in holdings rating. 2024Q1 revenue of 1.400 billion yuan (-37
Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy
04:44 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy Price (RMB): ¥80.99, Change: ¥+4.13, Percent Change: +5.37%
Gloria Ying (002821): Regular business achieved steady growth in Q1, profit margins in line with expectations
Matters: The company achieved revenue of 1,400 million yuan (-37.76%) in 24Q1, realized net profit of 282 million yuan (-55.27%), and net profit of 254 million yuan after deducting non-return to mother (-58.8 million yuan)
Gloria Ying (002821) 2024 Quarterly Report Review: Overseas Customer Revenue Increased Rapidly, Profitability Remained Steady
Event: On April 25, 2024, Gloria Ying released its 2024 quarterly report. The company achieved revenue of 1,400 billion yuan in Q1 of 2024, a year-on-year decrease of 37.76%, and a year-on-year increase after excluding the impact of large orders
Analysis
Price Target
No Data
